This study is looking at how a medication called Mydfrin (phenylephrine) can help doctors better understand the severity of mitral regurgitation (MR). MR is a condition where the heart's mitral valve doesn't close properly, causing blood to leak backward. When you have a transesophageal echocardiography (TEE) to check your MR, you are usually sedated, which can affect the results. Mydfrin is given through an IV to temporarily increase your blood pressure, mimicking how your heart works during normal activity. The goal is to see if Mydfrin helps show a more accurate picture of your MR severity, which can help doctors make better treatment decisions. To be eligible, you must be 18 or older, have MR, and be scheduled for a TEE. The study will be considered successful if at least 25% of patients show an increase in the amount of blood leaking backward after receiving Mydfrin during their TEE. The current status of this study is unclear.

Study design

This is an interventional study with a planned enrollment of 35 participants. It is not specified if the study is randomized or blinded.

What's involved

You would receive Mydfrin through an IV during your transesophageal echocardiography. Your blood pressure will be monitored, and additional doses of Mydfrin may be given over approximately 40 minutes.

Compensation

Not stated in the trial record.

Follow-up

Your mitral regurgitation will be measured before and after Mydfrin administration during the transesophageal echocardiography, which takes approximately 40 minutes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.